Stay updated on DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial

Sign up to get notified when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Revision updated from v3.5.3 to v3.5.4. This indicates a minor documentation/versioning update rather than changes to the study data or displayed content.
    Difference
    0.0%
    Check dated 2026-05-15T15:35:31.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    Results were posted on 2026-05-06 for the SPiReL trial, with detailed efficacy and safety outcomes. The update includes measures such as Objective Response Rate, Duration of Response, Time to Next Treatment, and related biomarker analyses.
    Difference
    2%
    Check dated 2026-05-08T12:12:03.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page’s displayed site revision has been updated from v3.5.2 to v3.5.3, indicating a general platform/UI release rather than a change to the study record content.
    Difference
    0.0%
    Check dated 2026-04-24T05:55:07.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:38:39.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    No additions or deletions were detected on the page.
    Difference
    0.1%
    Check dated 2026-04-02T15:23:53.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T06:11:26.000Z thumbnail image

Stay in the know with updates to DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the DPX-Survivac & Checkpoint Inhibitor in DLBCL Clinical Trial page.